Company Overview
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Why Investors Should Care
Revenue has grown at a 79.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $119.48M (+5.1% YoY); net profit $-81.65M.
- Trailing 12 Months Year-on-year growth — revenue -6.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 79.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 79.28% |
| 1 Year: | -6.30% |
Stock Price Performance
| 1 Year: | -75.86% |
| 6 Months: | -0.44% |
| 3 Months: | +5.34% |
| 1 Month: | +5.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 79.3% over 5 years.
CONS
- Trading 76.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OM Outset Medical, Inc. R2K | 4.54 | -1.66 | $84.16M | 0.00% | -29.40% | -53.17% | 79.28% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.49M | 2.87M | 2.63M | 7.08M | 7.19M | 11.74M | 13.76M | 17.25M | 22.92M | 25.22M | 26.32M | 30.55M | 25.06M | 27.76M | 33.47M | 36.04M | 30.36M | 28.17M | 27.39M | 28.67M | 29.75M | 31.42M | 29.43M | 27.86M |
| Gross Profit | -5.26M | -4.47M | -5.29M | -2.78M | -3.56M | -4.76M | -5.13M | 417.00K | 289.00K | 1.05M | 2.95M | 4.44M | 3.78M | 4.34M | 6.43M | 7.70M | 7.16M | 8.21M | 9.78M | 9.82M | 11.07M | 11.87M | 11.59M | 12.10M |
| Operating Income | - | - | -18.45M | - | -20.21M | -24.91M | -40.73M | - | -29.68M | -29.91M | -30.14M | -36.48M | -43.72M | -41.00M | -43.48M | -43.48M | -45.45M | -36.91M | -30.76M | -23.84M | -16.40M | -16.86M | -15.81M | -16.92M |
| Net Income | -16.42M | -17.03M | -15.40M | -19.45M | -20.65M | -26.50M | -42.29M | -32.04M | -30.02M | -30.21M | -30.47M | -36.89M | -43.84M | -40.78M | -43.97M | -44.05M | -46.18M | -39.94M | -34.45M | -27.94M | -25.78M | -18.54M | -17.84M | -18.98M |
| Diluted EPS | - | - | - | - | 0.74 | -4.58 | -3.44 | -0.75 | -0.70 | -0.66 | -0.65 | -0.78 | -0.92 | -0.85 | -0.90 | -0.90 | -0.93 | -11.77 | -9.96 | -8.02 | -3.66 | -1.04 | -1.00 | -1.03 |
| R&D Expense | - | - | 5.71M | - | 5.84M | 6.05M | 9.18M | - | 7.57M | 8.03M | 9.73M | 10.83M | 13.52M | 13.06M | 13.79M | 14.91M | 16.08M | 12.63M | 9.73M | 8.14M | 5.51M | 5.29M | 5.38M | 5.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.01M | 15.08M | 49.94M | 102.60M | 115.38M | 130.38M | 113.69M | 119.48M |
| Gross Profit | -6.12M | -17.80M | -13.04M | 7.61M | 17.83M | 29.00M | 38.56M | 46.75M |
| Operating Income | -46.56M | -70.31M | -117.47M | -130.52M | -161.02M | -169.77M | -113.38M | -66.71M |
| Net Income | -49.78M | -68.30M | -121.49M | -131.94M | -162.96M | -172.80M | -127.98M | -81.65M |
| Diluted EPS | - | - | -4.85 | -2.89 | -3.38 | -52.28 | -36.96 | -5.37 |
| R&D Expense | 22.92M | 23.33M | 28.85M | 36.74M | 48.85M | 57.31M | 38.40M | 21.23M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 88.37M | 403.83M | 463.46M | 400.12M | 313.80M | 275.80M | 264.50M |
| Total Equity | -215.94M | -287.95M | -372.19M | 328.61M | 374.08M | 245.99M | 122.89M | 26.82M | 126.95M |
| Cash & Equivalents | - | - | 36.93M | 294.97M | 182.35M | 73.22M | 68.51M | 124.01M | 35.01M |
| Long Term Debt | - | - | 21.56M | 29.67M | 29.76M | 96.34M | 130.11M | 197.38M | 96.24M |
| Total Liabilities | - | - | 51.11M | 75.22M | 89.38M | 154.12M | 190.91M | 248.98M | 137.54M |
| Current Liabilities | - | - | 24.91M | 36.69M | 51.70M | 51.95M | 55.32M | 45.38M | 37.63M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46.44M | -70.29M | -99.02M | -130.26M | -145.73M | -131.37M | -116.30M | -46.33M |
| Investing Cash Flow | -68.78M | 74.30M | 3.95M | -142.51M | -66.30M | 83.03M | 103.94M | -97.68M |
| Financing Cash Flow | 134.87M | 249.00K | 385.68M | 160.15M | 72.90M | 43.65M | 67.87M | 55.50M |
| Capital Expenditure | -1.77M | -3.29M | -9.08M | -3.11M | -8.32M | -3.44M | -912.00K | -798.00K |
| Free Cash Flow | -48.21M | -73.58M | -108.09M | -133.37M | -154.05M | -134.81M | -117.22M | -47.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -304.7% | -118.1% | -26.1% | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% |
| Operating Margin % | -2,320.0% | -466.3% | -235.2% | -127.2% | -139.6% | -130.2% | -99.7% | -55.8% |
| Net Margin % | -2,480.3% | -453.0% | -243.3% | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% |
| ROE % | 17.3% | 18.4% | -37.0% | -35.3% | -66.2% | -140.6% | -477.2% | -64.3% |
| ROCE % | - | -110.8% | -32.0% | -31.7% | -46.2% | -65.7% | -49.2% | -29.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.79% | 2.74M | $13.64M |
| 2 | BML Capital Management, LLC | 10.26% | 1.90M | $9.46M |
| 3 | Blackrock Inc. | 6.81% | 1.26M | $6.28M |
| 4 | Bank of America Corporation | 5.12% | 949.40K | $4.72M |
| 5 | Perceptive Advisors Llc | 4.50% | 833.33K | $4.15M |
| 6 | AQR Capital Management, LLC | 4.36% | 808.28K | $4.02M |
| 7 | Vanguard Capital Management LLC | 4.12% | 763.82K | $3.80M |
| 8 | Pfm Health Sciences, Lp | 3.21% | 594.63K | $2.96M |
| 9 | Ensign Peak Advisors, Inc | 2.84% | 526.59K | $2.62M |
| 10 | Assenagon Asset Management S.A. | 2.72% | 504.09K | $2.51M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OM
Pandox (OM:PNDX B) Stock Looks Cheap On Earnings Yet Mixed Elsewhere - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNeEUzalNQY2J1c1lMODU3QWJOcFpnM3FUNVpLWk1JWWZiUmJUTnRablh1Wi1DSzlVdFhILWMyM3ZwSW5aWVc2c2lGeU01RUxuZmtFRTlmcVJMZ25RM3Iwdk1XUmQ1TkozeTYxNkh5cUdBd1N2QkZfTjJqZUtJemFkQnhtcXR3cjNtNXZPX3…
5 Things to Know Before the Stock Market Opens on Monday - Investopedia
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaTl2LWtzSXhnUktqNW4zWmlEcjlkVHR3WVVlWWgtNnVxaG0zVF8wY2p5M2pIUzlqM2FGcFliMGFHaWNXLXkyNDh4cnVXSlU2RF8tSlN1bFpIMUNDWWVXaFRCX0hmd0kxTGtCZVdNSzNoYlNZRC14dGFBUk9ST3o3T1UyU2QybW14ZE9rdE…
Canadian Mining Stocks Report: Weekly Round-Up of 5 Top Performers - Investing News Network
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1lOXdSczkwZ19VLWVZY0o3alpYS2t3Q2lxelZOUGVrQWdWNmc4cHZFSXd3d095cngtRFQ0OW5tOG1zc3pfRmhPZmVTRzVBMFlySllpb19R?oc=5" target="_blank">Canadian Mining Stocks Report: Weekly Round-Up of 5…
The Best AI Stocks to Buy Now - Morningstar
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE5MSWticmVUcmhzVVpBMWg0bFpvRGpXR1FIdzhKMmVOdVVETlV0MzVfemFuMzBwX3Q2Ykh4TFRjakstUDZVX2N6NEpsSWxZZU54bTZnQmNMal9Fdkw3ei04N2htZldJYkhl?oc=5" target="_blank">The Best AI Stocks to Buy N…
OM Stock Price and Chart — TSX:OM - TradingView
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5yRl94UGt6UDZrd19FWlBJa0FlR0NBT09Ldm1SeHdRR3BSN3llMlRYUkR4VXRla0tqeDNxaHFxaHJCSDd0dWVuSVJCTlZzTGRHa2FkOE53?oc=5" target="_blank">OM Stock Price and Chart — TSX:OM</a> <f…
Volvo (OM:VOLV B) Stock After 114% Five-Year Gain Is There Value Left? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNLVhLZzhvZHU1cktlOW52V3NLUXhHbGg5TF9wcDJzcGZsMVkyY3JHNC1wZW5leGU1NFRsUHVNV0JoekNyX3ppZ0hPUXpuenNxYjJkNFVEVW1mS2I3b2hQaFVwajNjSFE3X1RUeTZfc1BVWmIxWF9OUmhGaTdacmhwTDZPNFhuUUswcFJ2Qk…
OM — Frequently Asked Questions
What is the current share price of Outset Medical, Inc. (OM)?
As of 2026-07-14 21:23 PDT, Outset Medical, Inc. (OM) trades at $4.54 on NasdaqGS. Its 52-week range is $3.16 to $19.44.
What is the market capitalisation of OM?
Outset Medical, Inc. (OM) has a market capitalisation of $84.16M on NasdaqGS.
What is the P/E ratio of OM?
OM trades at a trailing price-to-earnings (P/E) ratio of -1.66. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.74.
What is the return on equity (ROE) of OM?
OM has a return on equity (ROE) of -53.17%. Its return on capital employed (ROCE) is -29.40%.
Is OM a good stock to buy?
This page provides a data-driven analysis of Outset Medical, Inc. (OM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.